Literature DB >> 15816805

Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.

Igor Galynker, Asim Khan, Yuli Grebchenko, Aleksey Ten, Liliya Malaya, Philip Yanowitch, Lisa J Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15816805     DOI： 10.4088/jcp.v66n0420f

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  5 in total

Review 1.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 2.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

3.  Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study.

Authors:  Yi-Chih Chen; Chih-Ken Chen; Liang-Jen Wang
Journal:  BMC Psychiatry       Date:  2012-09-29       Impact factor: 3.630

4.  A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.

Authors:  James M Prosser; Samantha Yard; Annie Steele; Lisa J Cohen; Igor I Galynker
Journal:  BMC Psychiatry       Date:  2009-05-26       Impact factor: 3.630

5.  A review of quetiapine in combination with antidepressant therapy in patients with depression.

Authors:  Ella J Daly; Madhukar H Trivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.